V/Q Lung Scintigraphy: Physics & Dosimetry

Introduction

V/Q lung scintigraphy diagnoses pulmonary embolism by exploiting a deliberate, self-limiting physics trade-off: intravenous Tc-99m macroaggregated albumin (MAA) transiently plugs a minuscule fraction of the pulmonary microvasculature to map perfusion, while an inhaled agent maps ventilation—and a region that ventilates but does not perfuse signals a clot. The study is old, elegant, and still clinically essential, particularly where CT pulmonary angiography is contraindicated.¹⁹

The physics is what makes it both safe and interpretable. The MAA particle count is chosen to be large enough to produce a smooth perfusion image but small enough to occlude far less than 1% of the pulmonary capillary bed. The ventilation agent is chosen for its emission energy, its deposition behavior, and—in the case of Xe-133—its handling as a radioactive gas. And the imaging is increasingly tomographic, because V/P SPECT resolves segmental mismatch better than planar views.¹²⁸

This guide walks through the particle-number safety margin, the physics and dosimetry of each radiopharmaceutical, the radiation safety controls that a Xe-133 program requires, and why the field has shifted toward SPECT. DRPS supports these programs through its PET/CT and nuclear medicine physics and radiation safety officer services across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

The two halves of the study

A V/Q study is really two images acquired to be compared:

• Perfusion (Q). Intravenous Tc-99m MAA particles travel to the right heart, then lodge in pulmonary arterioles and capillaries in proportion to regional blood flow. Where flow is blocked—by an embolus—the particles cannot reach, and that region appears as a perfusion defect.¹
• Ventilation (V). An inhaled agent—Xe-133 gas, Tc-99m DTPA aerosol, or Technegas—distributes according to regional airflow. In pulmonary embolism, ventilation is typically preserved in the region that has lost perfusion.¹²

The diagnostic signature of acute pulmonary embolism is the mismatch: a region with normal ventilation but absent perfusion. Both the SNMMI and EANM frameworks define a clinically significant mismatch at the level of one segment or two subsegments.¹²

For related quantitative nuclear medicine procedures, see our articles on cardiac SPECT MPI quality control and SPECT/CT quality control.

Why blocking capillaries is safe

The idea of intentionally embolizing lung capillaries sounds alarming until the numbers are considered. A standard adult MAA dose contains a few hundred thousand particles—SNMMI cites a typical range of about 200,000–700,000 particles, and EANM notes roughly 400,000 are usually injected.¹² The pulmonary arteriolar and precapillary bed numbers in the hundreds of millions, so the occluded fraction is on the order of 0.1%—fewer than one vessel in a thousand. The aggregates also biodegrade over hours, so the blockage is transient.

This safety margin is not unlimited, which is why guidelines call for reducing the particle number in patients whose pulmonary bed is compromised or bypassed (discussed below).¹²

Key Technical Principles

The particle-number safety margin, quantified

The occluded fraction of the pulmonary microvascular bed is simply the ratio of injected particles to available vessels:

The denominator here is an order-of-magnitude estimate of the pulmonary arteriolar/precapillary population; the point is not the exact count but the three-orders-of-magnitude gap between particles injected and vessels available. That gap is the entire safety basis of perfusion imaging, and it shrinks in specific conditions:

• Pulmonary hypertension — the functional bed is reduced.
• Right-to-left shunt — particles can bypass the lungs and reach the systemic (including cerebral and coronary) circulation.
• Prior pneumonectomy or single-lung transplant — the entire dose is delivered to one lung.

In these situations, guidelines recommend cutting the particle count, commonly to roughly 100,000–200,000, while keeping activity high enough for a diagnostic image.¹² A single-institution analysis documented how routine this has become: the share of Tc-99m MAA doses given with a reduced particle number rose from 9% in 2000 to 47% in 2015, driven by growth in pulmonary-hypertension and transplant patients.⁵

The ventilation agents compared

Because Tc-99m DTPA aerosol and Technegas share the 140 keV Tc-99m photopeak and stay deposited, they support the same multi-projection and SPECT acquisitions as the perfusion study. Xe-133, at 81 keV, is imaged during a dynamic wash-in/wash-out sequence and cannot be re-projected after it clears. Technegas produces particles small enough to behave almost like a gas while penetrating to the periphery, which is why EANM prefers Technegas or krypton over DTPA aerosol in chronic obstructive pulmonary disease.²⁶⁷

Radiopharmaceutical physics and dosimetry

The relevant nuclear data:

• Tc-99m — 140 keV gamma, 6.0-hour physical half-life; ideal for gamma-camera imaging.
• Xe-133 — 81 keV principal gamma (about 38% abundance), 5.24-day physical half-life; a beta emitter decaying to stable Cs-133.

The whole-body effective dose is dominated by the perfusion agent. Using the approximate adult effective-dose coefficient for Tc-99m MAA of about 0.011 mSv/MBq from ICRP Publication 128, a 150 MBq perfusion dose gives:

Xe-133 is largely exhaled rather than retained, so its effective dose per unit administered activity is low (on the order of 10⁻³ mSv/MBq or less for rebreathing protocols).⁴ Consistent with these components, EANM reports a combined V/P study effective dose of about 1.2–2 mSv—roughly a third to a half of a dose-optimized CT pulmonary angiogram.³ For weight-based pediatric activity, see our guide to pediatric nuclear medicine dosing.

Clinical Impact

Planar versus V/P SPECT

The single biggest change in modern lung scintigraphy is the move from planar imaging to SPECT. Tomographic acquisition removes overlapping structures and resolves segmental defects that planar views blur together. The evidence is consistent: V/P SPECT has higher sensitivity and specificity than planar V/Q, and it produces fewer nondiagnostic studies. One series found V/P SPECT reduced indeterminate reports by 41% compared with planar scintigraphy, and that patients with only a single subsegmental mismatch rarely had confirmed embolism on follow-up.⁸ EANM now frames SPECT (or SPECT/low-dose CT) as the preferred technique.²

Where V/Q beats CT pulmonary angiography

CT pulmonary angiography (CTPA) is the default first-line test in many emergency settings, but it is not always the right one. The PIOPED II data placed CTPA sensitivity at about 83%, and CTPA carries iodinated-contrast risk, higher effective dose, and degraded performance in pregnancy.⁹ V/Q scintigraphy—particularly V/P SPECT—avoids contrast entirely and delivers a lower effective dose, which makes it the preferred pulmonary-embolism study in:

• pregnancy and young women (breast dose considerations),
• renal impairment or contrast allergy,
• patients needing serial follow-up of known embolism.

Collimator and acquisition choices

Both the 140 keV Tc-99m photopeak and the 81 keV Xe-133 photopeak are imaged with a low-energy collimator, but the acquisition differs: Xe-133 demands a rapid dynamic sequence during rebreathing, while Tc-99m ventilation and perfusion agents support standard multi-projection or SPECT acquisition. Collimator selection trades resolution against sensitivity; our article on gamma-camera collimator selection covers those trade-offs in depth.

Practical Optimization Tips

1. Match particle number to the patient

• Use standard particle counts for routine studies.
• Reduce to roughly 100,000–200,000 particles for pulmonary hypertension, right-to-left shunt, pneumonectomy, or single-lung transplant.¹²
• Keep activity adequate for image quality even when particle number is reduced.

2. Handle MAA correctly

• Avoid drawing blood back into the syringe, which can create labeled blood clots that image as hot spots.
• Gently resuspend particles immediately before injection to keep the count uniform.
• Inject with the patient supine to even out the anterior-to-posterior perfusion gradient.

3. Choose the ventilation agent deliberately

• Prefer Technegas or krypton over DTPA aerosol in COPD for better peripheral penetration.²
• Reserve Xe-133 for programs equipped with a validated rebreathing and trapping system.
• Use Tc-99m ventilation agents when SPECT ventilation imaging is desired.

4. Default to SPECT

• Acquire V/P SPECT (or SPECT/low-dose CT) where equipment allows, for fewer indeterminate reads.²⁸
• Interpret holistically (mismatch pattern) rather than by obsolete probabilistic rules.

Common pitfalls to avoid

• Forgetting to reduce particle number in high-risk physiology.
• Central aerosol clumping in obstructive disease, mistaken for defects—favor Technegas.
• Xe-133 leakage from an inadequate trapping system, contaminating room air.
• Treating a single subsegmental mismatch as diagnostic, when follow-up rarely confirms embolism.⁸

Regulatory Considerations

Lung scintigraphy is governed by professional procedure standards for how it is performed and by NRC or Agreement State radioactive-material rules for how the radiopharmaceuticals are handled. The controlling procedural documents are the SNMMI Practice Guideline for Lung Scintigraphy 4.0, the EANM guideline for V/P SPECT, and the ACR–SPR Practice Parameter for the Performance of Pulmonary Scintigraphy, which specify agents, activities, particle-number reductions, and interpretation criteria.¹²¹² Patient dosimetry references the coefficients compiled in ICRP Publication 128.⁴

Xe-133 introduces a distinct radiation safety layer because it is a radioactive gas. Programs administer it through a closed rebreathing system with a xenon trap to capture exhaled gas, in a room with appropriate ventilation and often negative pressure relative to adjacent areas, and they post spilled-gas clearance times. Airborne concentrations must stay within the limits of 10 CFR Part 20, and NRC guidance on procedures and precautions for radioactive gases describes the expected trapping and ventilation controls.¹⁰¹¹ The radiation safety officer verifies the trap, the room ventilation, and effluent controls as part of the program.

Jurisdiction follows the material, not the machine: the NRC (10 CFR Part 20 and Part 35) governs the Tc-99m and Xe-133 radiopharmaceuticals. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that administer these rules through their own radiation-control programs, while Washington, DC and Delaware are regulated directly by the NRC. Facilities should coordinate Xe-133 controls with their radiation safety officer program and, for handling and cleanup, our guidance on nuclear medicine decontamination best practices.

Frequently Asked Questions (FAQs)

What is V/Q lung scintigraphy?

V/Q lung scintigraphy is a nuclear medicine study that separately images pulmonary perfusion and ventilation and compares them. Perfusion is mapped with intravenous Tc-99m macroaggregated albumin (MAA), which lodges briefly in pulmonary capillaries; ventilation is mapped with an inhaled agent such as Xe-133 gas, Tc-99m DTPA aerosol, or Technegas. A region with preserved ventilation but absent perfusion—a mismatch—suggests pulmonary embolism.

Is it safe to inject particles that block lung capillaries?

Yes, because the number of particles is tiny relative to the pulmonary vascular bed. A typical adult dose contains a few hundred thousand MAA particles, while the lungs contain on the order of hundreds of millions of arterioles and precapillaries, so far less than about 0.1% of the bed is transiently occluded. The particles break down over hours. Particle numbers are deliberately reduced for patients with pulmonary hypertension or right-to-left shunt.

Why is the number of MAA particles reduced in some patients?

In pulmonary hypertension, right-to-left cardiac shunt, prior pneumonectomy, or single-lung transplant, the effective pulmonary capillary bed is smaller or partly bypassed, so a standard particle load could occlude a larger fraction of available vessels or reach the systemic circulation. Guidelines recommend reducing the particle number—commonly to roughly 100,000–200,000—while keeping activity adequate for imaging.

What are the physics differences between Xe-133, Tc-99m DTPA aerosol, and Technegas?

Xe-133 is a radioactive gas (81 keV photopeak, 5.24-day half-life) that requires a closed rebreathing system and room ventilation controls. Tc-99m DTPA aerosol and Technegas both use the 140 keV Tc-99m photopeak and deposit in the airways and alveoli, allowing multiple projections or SPECT. Technegas produces ultrafine carbon-encapsulated particles with better peripheral penetration, which is advantageous in obstructive lung disease.

What radiation dose does a V/Q scan deliver?

A combined ventilation–perfusion study delivers a whole-body effective dose on the order of 1.2–2 mSv, depending on the agents and administered activities. The perfusion component (Tc-99m MAA at roughly 40–150 MBq) contributes most of the effective dose; Xe-133 is largely exhaled, so its effective dose per unit activity is low.

What special radiation safety applies to Xe-133?

Because Xe-133 is a gas, it must be administered through a closed rebreathing/trapping system, in a room with appropriate ventilation and often negative pressure relative to surrounding areas, with a xenon trap to capture exhaled gas. Facilities post spill clearance times and keep airborne concentrations within 10 CFR Part 20 limits. The radiation safety officer verifies the trapping and ventilation controls.

Why choose V/Q over CT pulmonary angiography?

V/Q scintigraphy—especially V/P SPECT—avoids iodinated contrast and delivers a lower effective dose than CT pulmonary angiography, which makes it valuable in pregnancy, renal impairment, contrast allergy, and young patients. V/P SPECT has higher sensitivity and specificity than planar imaging and fewer indeterminate results, though CTPA remains preferred in some clinical scenarios.

Key Takeaways

• V/Q imaging is a mismatch detector: preserved ventilation with absent perfusion signals pulmonary embolism, defined at one segment or two subsegments.
• The particle-number safety margin is ~0.1%—a few hundred thousand MAA particles against a bed of hundreds of millions of vessels—and it must be reduced (to ~100,000–200,000) in pulmonary hypertension, right-to-left shunt, or single-lung physiology.
• Ventilation agents differ in physics: Xe-133 (81 keV gas, needs trapping), Tc-99m DTPA aerosol and Technegas (140 keV, deposited, SPECT-capable); Technegas penetrates best in COPD.
• A combined study is ~1.2–2 mSv, lower than CTPA and contrast-free, favoring V/Q in pregnancy and renal impairment.
• Xe-133 requires engineered controls: closed rebreathing, xenon trap, room ventilation, and effluent limits under 10 CFR Part 20.
• V/P SPECT beats planar imaging, cutting indeterminate reports substantially.

Conclusion

V/Q lung scintigraphy endures because its physics is sound and its safety margin is enormous: a perfusion image built from particles that occlude a fraction of a percent of the pulmonary bed, paired with a ventilation image whose agent is chosen for emission energy and deposition behavior. The details that make the study work—matching particle number to the patient's physiology, selecting the right ventilation agent, controlling Xe-133 as a radioactive gas, and defaulting to SPECT—are exactly the details a nuclear medicine physicist and radiation safety officer are responsible for.

Done well, V/Q remains a low-dose, contrast-free, highly specific test for pulmonary embolism, and an indispensable alternative when CT angiography is contraindicated. Done carelessly—standard particle counts in the wrong patient, a leaking xenon trap, planar-only imaging—it forfeits both its safety and its diagnostic edge.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine departments running lung scintigraphy programs. That work includes gamma-camera and SPECT performance testing, protocol and dosimetry review for ventilation and perfusion agents, radiation safety evaluation of Xe-133 rebreathing and trapping systems and room ventilation, effluent and airborne-concentration assessments, and radiation safety officer support aligned with NRC and Agreement State requirements.

DRPS serves facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware. A defensible V/Q program pairs good imaging physics with disciplined radiation safety.

Related Resources

• Cardiac SPECT MPI quality control
• SPECT/CT quality control
• Gamma-camera collimator selection
• Pediatric nuclear medicine dosing
• Nuclear medicine decontamination best practices
• PET/CT and nuclear medicine physics
• Radiation Safety Officer consulting
• Medical physicist consulting

References

1. Parker JA, Coleman RE, Grady E, Royal HD, Siegel BA, Stabin MG, Sostman HD, Hilson AJW. SNM practice guideline for lung scintigraphy 4.0. Journal of Nuclear Medicine Technology. 2012;40(1):57-65. doi:10.2967/jnmt.111.101386. PubMed
2. Bajc M, Schümichen C, Grüning T, Lindqvist A, Le Roux PY, Alatri A, Bauer RW, Dilic M, Neilly B, Verberne HJ, Delgado Bolton RC, Jonson B. EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. European Journal of Nuclear Medicine and Molecular Imaging. 2019;46(12):2429-2451. doi:10.1007/s00259-019-04450-0. PubMed
3. Bajc M, Neilly JB, Miniati M, Schuemichen C, Meignan M, Jonson B. EANM guidelines for ventilation/perfusion scintigraphy: Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. European Journal of Nuclear Medicine and Molecular Imaging. 2009;36(8):1356-1370. doi:10.1007/s00259-009-1170-5. PubMed
4. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Annals of the ICRP. 2015;44(2 Suppl). icrp.org
5. Ponto JA. Changes in Patterns of Tc-99m-Macroaggregated Albumin Use Between 2000 and 2015. Journal of Nuclear Medicine Technology. 2017;45(2):111-113. doi:10.2967/jnmt.117.192401. PubMed
6. Sullivan PJ, Burke WM, Burch WM, Lomas FE. A clinical comparison of Technegas and xenon-133 in 50 patients with suspected pulmonary embolus. Chest. 1988;94(2):300-304. doi:10.1378/chest.94.2.300. PubMed
7. Satoh K, Takahashi K, Sasaki M, Kobayashi T, Honjo N, Ohkawa M, Tanabe M, Fujita J, Miyawaki H. Comparison of 99mTc-Technegas SPECT with 133Xe dynamic SPECT in pulmonary emphysema. Annals of Nuclear Medicine. 1997;11(3):201-206. doi:10.1007/BF03164764. PubMed
8. Stubbs M, Chan K, McMeekin H, Navalkissoor S, Wagner T. Incidence of a single subsegmental mismatched perfusion defect in single-photon emission computed tomography and planar ventilation/perfusion scans. Nuclear Medicine Communications. 2017;38(2):135-140. doi:10.1097/MNM.0000000000000632. PubMed
9. Leblanc M, Paul N. V/Q SPECT and computed tomographic pulmonary angiography. Seminars in Nuclear Medicine. 2010;40(6):426-441. doi:10.1053/j.semnuclmed.2010.08.001. PubMed
10. U.S. Nuclear Regulatory Commission. Procedures and Precautions for Use of Radioactive Gases (ADAMS Accession No. ML070680056). nrc.gov
11. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
12. American College of Radiology. ACR–ACNM–SNMMI–SPR–STR Practice Parameter for the Performance of Pulmonary Scintigraphy. Revised 2023. acr.org